Forest & Almirall Announce Positive Results from the ACCORD COPD I Phase III Study of aclidinium bromide in Chronic Obstructi...
January 07 2010 - 2:30AM
Business Wire
Forest Laboratories, Inc. (NYSE: FRX) and Almirall, S.A.
(ALM.MC) today announced positive top-line results from ACCORD COPD
I, a three-month Phase III study comparing aclidinium 200µg and
400µg BID versus placebo. Aclidinium bromide produced statistically
significant (p
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Oct 2023 to Oct 2024
